Drugs / GSK1521498
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT01738867 | Dec 2012 → May 2014 | alcohol dependence | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT01366573 | May → Sep 2011 | alcohol dependence | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00976105 | Sep 2009 → Mar 2010 | obesity disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00976066 | Jun → Dec 2009 | obesity disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01195792 | Sep 2010 → May 2011 | obesity disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT00857883 Comparator | Nov 2008 → Aug 2009 | obesity disorder | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK1521498 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00857883 ↗ |
| Known as | GSK1521498H | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297383 ↗ |
| Action | Inhibit | “This may stop the natural effect of opioids” NCT00857883 ↗1“Mu opioid receptor antagonist” CHEMBL4297383 ↗ |
| Modality | Small molecule | — CHEMBL4297383 ↗ |
| Route | Oral | “single oral doses of GSK1521498” NCT00976066 ↗ |
| Target | OPRM1 | “Mu opioid receptor antagonist” CHEMBL4297383 ↗ |